Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients
Autor: | Javier Padillo-Ruiz, Gonzalo Suarez, Sheila Pereira, Francisco José Calero-Castro, Jose Tinoco, Luis Marin, Carmen Bernal, Carmen Cepeda-Franco, Jose Maria Alamo, Francisco Almoguera, Hada C. Macher, Paula Villanueva, Francisco José García-Fernandez, Inmaculada Gallego, Manuel Romero, Miguel Angel Gomez-Bravo, Valeria Denninghoff, María José Serrano |
---|---|
Přispěvatelé: | Instituto de Salud Carlos III, European Commission |
Rok vydání: | 2021 |
Předmět: |
Cancer Research
Circulating tumor cell Early stage pancreatic cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens central venous catheter Death risk stratification Pancreatic cancer early stage circulating tumor cell Article Oncology Cluster Portal vein cluster portal vein death risk stratification Central venous catheter RC254-282 |
Zdroj: | Cancers Cancers, Vol 13, Iss 6153, p 6153 (2021) Digibug. Repositorio Institucional de la Universidad de Granada instname Cancers; Volume 13; Issue 24; Pages: 6153 Digital.CSIC. Repositorio Institucional del CSIC |
ISSN: | 2072-6694 |
Popis: | [Simple Summary] Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of circulating tumor cells and clusters from the central venous catheter and portal blood. Circulating tumor cells were isolated using an immunomagnetic selection and were detected by microscopy using immunocytochemistry staining. In conclusion, the circulating tumor cell number in portal blood identifies a death risk in patients with early pancreatic cancer. [Abstract] Background. Effective biomarkers are needed to enable personalized medicine for pancreatic cancer patients. This study analyzes the prognostic value, in early pancreatic cancer, of single circulating tumor cell (CTC) and CTC clusters from the central venous catheter (CVC) and portal blood (PV). Methods. In total, 7 mL of PV and CVC blood from 35 patients with early pancreatic cancer were analyzed. CTC were isolated using a positive immunomagnetic selection. The detection and identification of CTC were performed by immunocytochemistry (ICC) and were analyzed by Epi-fluorescence and confocal microscopy. Results. CTC and the clusters were detected both in PV and CVC. In both samples, the CTC number per cluster was higher in patients with grade three or poorly differentiated tumors (G3) than in patients with well (G1) or moderately (G2) differentiated. Patients with fewer than 185 CTC in PV exhibited a longer OS than patients with more than 185 CTC (24.5 vs. 10.0 months; p = 0.018). Similarly, patients with fewer than 15 clusters in PV showed a longer OS than patients with more than 15 clusters (19 vs. 10 months; p = 0.004). These significant correlations were not observed in CVC analyses. Conclusions. CTC presence in PV could be an important prognostic factor to predict poor prognosis in early pancreatic cancer. In addition, the number of clustered-CTC correlate to a tumor negative differentiation degree and, therefore, could be used as a diagnostic biomarker for pancreatic cancer. This research was funded by Carlos III Health Institute (Health Research Fund) grant number PI16/01465 and PI19/01821 (Co-financed by the European Regional Development Fund “A way to make Europe”). |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |